User:Charlotte O Jane

Scientific contribution
Stefan D. Anker, MD, PhD, FESC, is a Professor of Innovative Clinical Trials at University Medical Center Göttingen in Germany. The main focus of the Innovative Clinical Trials department is research in the field of chronic heart failure, including the development and clinical testing of new therapies.

He was previously Professor of Cardiology and Cachexia Research at Charité Medical School of Humboldt-University Berlin, Germany between 2002 and 2014.

He studied medicine at Charité Medical School of Humboldt-University Berlin, Germany (1987-1993) and completed his PhD at the National Heart and Lung Institute of Imperial College London, United Kingdom, in 1998. Since then, he has had teaching appointments in several countries (UK, Germany, Australia, Italy).

His particular research interests include the pathophysiology and treatment of acute and chronic heart failure (CHF), cardiac device therapy, clinical evaluation of cardiovascular biomarkers, pathophysiology of muscle wasting, cachexia therapy in CHF, ageing, sarcopenia and cancer.

Stefan Anker is a member of and serves on the Boards of several academic organisations. He serves on the editorial boards of five scientific journals (including European Heart Journal and European Journal of Heart Failure ). He is founding Editor-in-Chief of the Journal of Cachexia, Sarcopenia and Muscle and of ESC Heart Failure, which is the first open access heart failure journal.

Stefan Anker has won several prizes (including two American Heart Association Young Investigator Awards ), and has obtained a number of fellowships and grants, including two National Institutes of Health (NIH) grants (Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial ), two grants from the EU’s Seventh Framework Programme for Research (FP7), and one Innovative Medicines Initiative / Horizon 2020 grant.

Memberships
Stefan Anker has been a member of the German Cardiac Society and of the European Society of Cardiology (ESC) since 1995. He is currently Vice President of the ESC in charge of National Cardiac Societies and Communications. He has been serving on the board of the ESC since 2012. In addition, he has been serving on the board of the Heart Failure Association (HFA) of the ESC since 2006. He was HFA President between 2012 and 2014 and he currently chairs the HFA committee on regulatory affairs.

Stefan Anker is the Founding President of the International Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD).

Publications
Stafan Anker has authored more than 700 original papers, reviews, and editorials. Total citations exceed 46,000, including over 50 papers with more than 200 citations. He has an h-index of 104. Main topics are heart failure, chronic disease, cachexia and biological markers.

 

Selected bibliography

 * 1) Anker SD, Ponikowski P, Varney S, et al. Wasting as independent risk factor of survival in chronic heart failure. Lancet 1997;349:1050-3.
 * 2) Anker SD, Chua TP, Swan JW, et al. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure: The importance for cardiac cachexia. Circulation 1997;96:526-34.
 * 3) Niebauer J, Volk H-D, Kemp M, et al & Anker SD. Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet 1999;353:1838-42.
 * 4) Rauchhaus M, Coats AJS, Anker SD. The endotoxin-lipoprotein hypothesis. Lancet 2000;356:930- 3.
 * 5) Anker SD, Negassa A, Coats AJS, et al. Prognostic importance of weight loss in chronic heart and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study. Lancet 2003;361:1077-83.
 * 6) Anker SD, Doehner W, Rauchhaus M, et al. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation 2003;107:1991-7.
 * 7) Anker SD, Comin Colet J, Filippatos G, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009;361:2436-48.
 * 8) Maisel A, Mueller C, Nowak R, Peacock WF et al. & Anker SD. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol. 2010;55:2062-76.
 * 9) Koehler F, Winkler S, Schieber M, et al. & Anker SD. Impact of Remote Telemedical Management on Mortality and Hospitalizations in Ambulatory Patients With Chronic Heart Failure: The TIM-HF Study. Circulation 2011;123:1873-80.
 * 10) Anker SD, Koehler F, Abraham WT. Telemedicine and remote patient management in heart failure. Lancet 2011;378:731-9.
 * 11) von Haehling S, Schefold JC, Jankowska EA, et al. & Anker SD. Ursodeoxycholic acid in patients with chronic heart failure a double-blind, randomized, placebo-controlled, crossover trial. J Am Coll Cardiol. 2012;59:585-92.
 * 12) Homma S, et al. WARCEF Investigators. Warfarin and aspirin in patients with heart failure and sinus rhythm. Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med. 2012;366:1859-69.
 * 13) Ponikowski P, et al. & Anker SD. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J. 2015;36,657–68.

Consensus meetings and guidelines
Stefan Anker has participated in and chaired several consensus meeting and guidelines committees:
 * 1) Chair, ESPEN Guidelines on Parenteral Nutrition: on cardiology and pneumology. (Anker et al., Clin Nutr 2009)
 * 2) Co-Chair, Consensus Group “The definition of Cachexia” (Evans et al., Clinical Nutrition 2008)
 * 3) AHA Consensus Group “State of the science: promoting self-care in persons with heart failure: a scientific statement from the American Heart Association.” (Riegel et al., Circulation 2009)
 * 4) ADQI 7 Consensus Group “Cardio-Renal Syndromes” (Ronco et al., Eur Heart J 2010)
 * 5) Co-Chair, Consensus Group “Endpoints for Cachexia Trials & Nutrition for Cachexia and Sarcopenia” (Morley et al., JAMDA 2010)
 * 6) Nutritional recommendations for the management of sarcopenia. Co-Chair. (Morley el al., JAMDA 2010)
 * 7) “Definition and classification of cancer cachexia” (Fearon et al. Lancet Oncol 2011)
 * 8) ESC/HFA Guideline on Diagnosis & treatment of acute and chronic heart failure (McMurray et al., EHJ 2012)
 * 9) HFA/WGTE of ESC Consensus on thromboembolism & anti-thrombotic therapy in heart failure with sinus rhythm (Lip et al. Eur J HF 2012)
 * 10) ESH/ESC Guidelines for the management of arterial hypertension. Reviewer. (Mancia et al. EHJ 2013)
 * 11) ESC/EASD Guidelines on diabetes, pre-diabetes, and cardiovascular diseases. (Ryden et al. EHJ 2013)
 * 12) SC/ESA 2014 Guidelines on non-cardiac surgery: cardiovascular assessment and management. (Kristensen et al. EHJ 2014)
 * 13) Reporting on patient reported outcomes in cardiovascular trials – Position statement of the ESC cardiovascular round table. (Anker et al. EHJ 2014)
 * 14) ESC/HFA Guideline on Diagnosis & treatment of acute and chronic heart failure (Ponikowski et al., EHJ 2016)
 * 15) Co-Chair, Consensus Group “International Cachexia Definition – Update 2016” (ongoing)

Research
Stefan Anker has been a member of more than 30 international clinical trial steering committees, chairing or co-chairing more than 10 (including the FAIR-HF, TIM-HF , BACH , AUGMENT-HF , ACT-ONE , RESHAPE-HF2 , IMPULSE-HF , FAIR-HF2 , Fair-HFpEF , EMPORER-HFpEF trials ). He served in several data and safety monitoring boards (chairing five) and end-point committees (chairing three). In 2015 and again in 2016, he was named in the Thomson Reuters Highly Cited Researchers list.

Honors and awards

 * 22/10/1998: "Ehrenmedalie der Charité Berlin" (honorary medal of Charité Medical School, Berlin)
 * 11/1998: Runner-up; Samuel A. Levine Young Investigator Award [YIA] (Clinical Cardiology) of the AHA for the paper: Niebauer J, Poole-Wilson PA, Coats AJS, Anker SD. Endotoxin and immune activation in chronic heart failure: proof of concept.
 * 3/1999: 2nd Prize; Young Investigator Award (Clinical Cardiology) of the ACC for the paper: Ponikowski P, Anker SD, Coats AJS. Oscilatory breathing patterns during the wakefulness in patients with chronic heart failure: clinical and prognostic implications.
 * 8/2000: 3rd Prize; YIA Clinical Cardiology of the European Society of Cardiology for the paper: Anker SD, Negassa A, Coats AJS, Poole-Wilson PA, Yusuf S. Prognostic importance of weight loss in chronic heart failure and the impact of treatment with ACE inhibitors.
 * 11/2000: 1st Prize; Samuel A. Levine Young Investigator Award (Clinical Cardiology) for the AHA for the paper: Sharma R, Coats AJS, Anker SD. Cellular endotoxin desensitization in patients with severe chronic heart failure.
 * 2/2001: GlaxoSmithKline Respiratory Clinical Research Award (£38,358)
 * 5/2006: Animal protection research prize (22,000 EUR) (together with Dr. Springer)
 * 11/2006: 1st Prize; Samuel A. Levine Young Investigator Award (Clinical Cardiology) for the AHA for the paper: Okonko D, Poole-Wilson PA, Anker SD, Ponikowski P. Intravenous iron therapy in patients with chronic heart failure with and without anemia.
 * 6/2007: 1st Prize; Young Investigator Award of the European HF Association for the paper: Okonko D, Anker SD, Poole-Wilson PA. Epo and inflammatory cytokines in patients with chronic heart failure – mechanistic studies.
 * 10/2011: Storz German Telemedicine Award 2011 for TIM-HF (together with Prof. Köhler)

References and external links

 * PubMed


 * ScienceDirect


 * Journal of Cachexia, Sarcopenia and Muscle
 * JACC
 * American Journal of Cardiology
 * Circulation
 * Journal of Cardiac Failure
 * The Lancet
 * Circulation Heart Failure
 * New England Journal of Medicine
 * International Society on Cachexia, Sarcopenia & Wasting Disorders
 * Google Scholar
 * Clarivate Analytics